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Abstract 
 
Background  
 
Perioperative myocardial injury (PMI) remains a major cause of perioperative morbidity 
and mortality but clinical strategies to prevent PMI are still uncertain.  
 
Methods and Results  
 
We comprehensively searched PubMed for major research articles concerning clinical 
strategies to prevent PMI. The key findings are as follows: (1) the American College of 
Cardiology/American Heart Association guideline update for perioperative cardiovascular 
evaluation for noncardiac surgery is very useful to stratify cardiac risk preoperatively; (2) 
cardiac troponin has emerged as a biomarker to diagnose postoperative PMI and to predict 
clinical outcomes; (3) coronary revascularization before noncardiac surgery probably 
would provide cardiac protection in select patients, especially in patients with high-risk 
coronary artery disease; (4) elective noncardiac surgery should be postponed in patients 
who received coronary stenting recently because of high incidence of serious cardiac 
complications (minimum 68 weeks for bare metal stents and 6-12 months for drug-eluting 
stents); and (5) β-blockers and statins are very promising drugs and probably would 
prevent PMI in a select patient population, especially in patients with intermediate risk 
and stable coronary artery disease.  
 
Conclusions  
 
Further studies, especially randomized clinical trials and mechanistic investigation are 
needed to find the best and effective clinical strategies to prevent/reduce PMI. (Am 
Heart J 2007;154:1021-8.)  
 
 
 
Perioperative myocardial injury (PMI), including myocardial ischemia, cardiac 
dysfunction, cardiac arrhythmias, myocardial infarction, and cardiac arrest continues to be 
a major challenge to perioperative physicians because its incidence has not substantially 
decreased for the past 2 decades.1,2  Despite extensive clinical and basic research, the 
mechanisms responsible for PMI remain enigmatic. Currently, the predominant theories 
are that PMI may be caused by prolonged stress- induced myocardial ischemia, 
atherosclerotic plaque rupture, or a combination of the two. Clinically, perioperative 
myocardial ischemia and infarction may present differently; pathologically, they are all 
secondary to alterations of coronary plaque morphology and function and/or the loss of 
balance between myocardial oxygen supply and demand, in which inflammation has been 
linked with the development of atherosclerotic disease and instability and may cause acute 
coronary syndromes (ACSs) and PMI. 
 
 
The potential triggers for PMI include surgical stress, catecholamine release, and 
inflammatory reaction; prolonged/repeated stress or extreme surgical stress especially may 
inflict inflammation and induce repeated/prolonged myocardial ischemia, which may 
serve as a primary cause for PMI, including perioperative myocardial infarction. Several 
lines of evidence support this hypothesis. First, perioperative cardiac complications are 
preceded almost universally by long-rather than short-  duration ST-segment changes—an 
indication of pro-longed myocardial ischemia.3,4  Second, most perioperative myocardial 
infarctions occur early after surgery (most  stressful time) and are asymptomatic (“silent” 
myocardial infarction)5,6; most of them are preceded by episodes of increases in heart 
rate4,6 and show non–Q wave rather than Q wave myocardial infarction,3,5 whereas 
clinical studies have well demonstrated that complete coronary occlusion is infrequently 
observed in patients with non–Q wave myocardial infarction (only 26%-42%) compared 
with patients with Q wave infarction (≥84%).7 Third,  β-adrenergic receptor blockers, 
because of their inherent role of blocking sympathetic activation, have been shown to 
reduce perioperative ischemia and the risk of myocardial infarction and death in high-risk 
surgical patients (see below). Finally, our recent study demonstrated that chronic 
catecholamine stimulation can aggravate myocardial injury by provoking
 
inflammatory 
reaction and increasing myocardial  apoptosis, thereby illustrating a mechanistic link 
between extreme/prolonged surgical stress → catecholamine release → 
inflammation/myocardial apoptosis and PMI.8
 
Nevertheless, coronary plaque disruption was found in more than half of fatal 
perioperative myocardial infarctions and was considered as a primary cause of fatal 
perioperative myocardial infarction.
9,10 
More likely, surgery, especially major surgery with 
its associated trauma, anesthesia, pain, bleeding, and hypothermia, is comparable to an 
extreme stress test, thereby producing a triggering/provoking effect in the pathogenesis of 
PMI (ie, inflicting inflammation and destabilizing plaques) and ultimately leading to 
appearance of PMI.  
 
 
Clinical strategies to prevent PMI have been evolving greatly. In 1977, Goldman et al
11 
pioneered the concept of a risk index to account for the multifactorial nature of 
contributors to risk of cardiac morbidity, which has led to the landmark development in 
perioperative medicine, that is, the American College of Cardiology (ACC)/ American 
Heart Association (AHA) guidelines for perioperative cardiovascular evaluation for 
noncardiac surgery in 1996
12 
and an update in 2002.
13 
These guidelines focused on 
preoperative testing to identify patients with significant coronary artery disease (CAD) 
and subsequent coronary revascularization in select patients. The guidelines currently play 
a major role in perioperative medicine. However, because of the poor positive predictive 
value of noninvasive cardiac stress tests, the controversy about the benefit of coronary 
revascularization before noncardiac surgery, and the considerable risk of coronary 
angiography and coronary revascularization in high-risk patients, perioperative physicians 
have been continuously searching for alternative approaches to prevent/reduce 
perioperative cardiac complications. In 1996, Mangano et al
14 
performed a randomized 
clinical trial (RCT) to investigate the effect of the β-blocker, atenolol, on patient outcomes 
and concluded that in patients with risk for CAD who must undergo noncardiac surgery, 
treatment with atenolol during hospitalization can reduce mortality and the incidence of 
cardiovascular complications for as long as 2 years after surgery. In 2003, Poldermans et 
al 
15 
provided evidence in a case-controlled study that statin use reduces perioperative 
mortality in patients undergoing major vascular surgery. More recently, the ACC/ AHA 
updated their recommendations on perioperative βblocker therapy. 
16 
These significant 
developments in perioperative medical therapy to prevent/reduce PMI have shifted the 
interest in perioperative cardiac care greatly, from risk stratification and potential coronary 
revascularization to risk modification with β-blockers and/or statins. Nevertheless, the 
debate and controversy exist in almost every aspect of clinical strategies to prevent PMI. 
These strategies include mainly preoperative cardiac risk assessment, perioperative 
monitoring, prophylactic coronary revascularization, coronary stents, and perioperative 
medical therapy.  
 
 
Preoperative cardiac risk assessment  
 
The ACC/AHA guideline update for perioperative cardiovascular evaluation for 
noncardiac surgery can help to stratify cardiac risk and identify the patients who need 
preoperative interventions to reduce cardiac risk.
13 
The rationale for intensive screening is 
based on the assumption that coronary revascularization prevents PMI in patients with 
CAD. As the ACC/AHA task force stated in the guideline: “A large proportion of the data 
used to develop these guidelines are based on observational or retrospective studies or 
knowledge of management of cardiovascular disorders in the nonoperative setting. 
Although the collective body of knowledge about the identification of high-and low-risk 
patients by perioperative clinical and noninvasive evaluation is substantial, the number of 
prospective or randomized studies that have been performed to establish the value of 
different treatments on perioperative outcomes is small.”
13 
Based on the guidelines, many 
patients undergo preoperative testing for detection of CAD before noncardiac surgery. 
However, noninvasive cardiac stress testing for perioperative myocardial infarction or 
death has very poor positive predictive values (b20%), although it has excellent negative 
predictive values (near 100%).17 Therefore, there is uncertainty and much debate on how 
to prepare surgery for the patient who has positive results from preoperative cardiac stress 
testing, that is, medical therapy versus coronary revascularization. In addition, very few 
RCTs support either of the treatments (see below).  
 
 
The Lee et al 
18 
revised cardiac risk index is a simple and practical clinical risk index. It 
includes 6 variables to identify patients at high risk for perioperative cardiac 
complications: history of CAD, history of congestive heart failure, history of cerebral 
vascular accident, preoperative insulin treatment, serum creatinine level N2.0 mg/dL, and 
high-risk surgical procedure. The presence of 3 or more of these risk variables (class III 
and IV) conferred an event rate as high as 11% in a group of 1422 patients, whereas the 
event rate was b1% in the presence of one or none of these variables (class I and II).18  
 
 
Other investigators also approached the problem of assessing PMI risk through the 
development of multivariate models; they proposed that the expected risk from these risk 
indices may vary along institutions 
19 
and a test required by these indices should only be 
performed if this has consequences on perioperative management.
13 
And this is why 
routine electrocardiogram and chest x-ray have been abandoned as preoperative tests in 
low− and intermediate-risk surgical patients without specific indications.  
 
 
Perioperative monitoring  
 
Cardiac troponin I (cTnI) and cTnT have become the biomarkers of choice to diagnose 
myocardial infarction and to risk-stratify patients with suspected ACS. A recent study by 
Wong et al
20 
demonstrated that cTn elevations were associated with a higher risk of 
multi-vessel disease, complex lesion morphology, and visible thrombus on coronary 
angiography. Moreover, such patients had more impairment in microvascular function, 
thereby suggesting a greater propensity for distal embolization of plaque material to the 
microvasculature. Recently, intravascular ultrasound studies have illustrated that those 
patients with ACS and elevated troponin levels had greater atheroma burden at the lesion 
site, more reference segment atherosclerosis, and more frequent findings compatible with 
thrombus at the lesion compared with patients who did not have troponin elevation.
21 
Taken together, these findings likely explain the consistent association between troponin 
elevation, even at low levels, and recurrent ischemic events in patients with ACS. 
 
In surgical patients, Landesberg et al
22 
and Kim et al
23 
have demonstrated that 
postoperative cTn measurements can detect postoperative myocardial infarction and 
predict short-term (6 months) and long-term (1-5 years) survival after vascular surgery. 
Recently, in a study with intense postoperative cTnI surveillance in 1136 patients who 
underwent abdominal aortic surgery, Le Manach et al 
24 
revealed 2 types of PMI according 
to the time of appearance and rate of increase in cTnI: acute (b24-hour) and early 
increases of cTnI above threshold may indicate acute coronary occlusion for early 
morbidity; prolonged low-level cTnI release followed by a delayed (N24 hours) increase 
of cTnI may lead to prolonged myocardial ischemia for later events. They proposed 
monitoring perioperative cTnI concentrations and early institution of treatment for patients 
with increased cTnI before it leads to irreversible necrosis.  
 
Recently, Mahla et al 
25 
investigated the use of cardiac stress marker, N-terminal pro–brain 
natriuretic peptide (NT-proBNP), to stratify PMI risk in patients undergoing vascular 
surgery and found that a single postoperative NT-proBNP determination provides 
important additional prognostic information for inhospital and late cardiac events and 
therefore may support therapeutic decisions to prevent subsequent myocardial damage. 
This study again provides evidence that the extent of surgical stress is closely related with 
risk of PMI.  
 
Despite the progress in clinical application of biomarkers for myocardial injury, such as 
cTn as a marker of myocardial necrosis, there is still a lack of markers of myocardial 
ischemia, especially the biomarkers that  
(1) can detect myocardial ischemia without myocardial necrosis,  
(2) increase the size of release proportional to the extent of ischemia,  
(3) appear in circulation rapidly after onset of ischemia and last long enough for the 
detection, and  
(4) are easy to measure with high sensitivity and reasonable specificity.  
 
 
Prophylactic coronary revascularization  
 
The role of prophylactic/preoperative coronary revascularization in patients with CAD 
before noncardiac surgery has been examined carefully in several clinical studies but 
remains controversial. ACC/AHA guidelines update recommended coronary 
revascularization only for subgroups of high-risk patients with unstable cardiac symptoms 
or those for whom coronary artery revascularization offers a long-term benefit, 
independent of the need for noncardiac surgery.
13 
This recommendation was based 
predominately on the CASS
26 
as follows.  
  
 
Coronary artery bypass graft before noncardiac surgery  
 
In 1997, the CASS investigators reported their study, which is the largest study to date and 
included 3368 noncardiac operations performed within a 10-year period among patients 
assigned to medical therapy or coronary artery bypass graft (CABG). In this study they 
found that among 1961 patients undergoing higher risk surgery (involving the thorax, 
abdomen, vasculature, and head and neck), prior CABG was associated with fewer 
postoperative deaths (1.7% vs 3.3%, P = .03) and myocardial infarctions (0.8% vs 2.7%, P 
= .02) compared with medically managed CAD. There was no difference in the outcome 
of patients undergoing low-risk procedures such as breast and urologic surgery. They 
concluded that “in patients with known CAD, noncardiac surgeries involving the thorax, 
abdomen, vasculature, and head and neck are associated with the highest cardiac risk, 
which is reduced among patients with prior CABG.”
26 
However, major limitations of the 
CASS are that the mortality and morbidity associated with CABG was not factored into 
the analysis of perioperative outcomes and that perioperative medical treatments, such as 
perioperative β-blocker and statin therapy, have undergone major improvements since the 
study was published 10 years ago.  
 
Coronary revascularization before vascular surgery  
 
In the CARP trial, however, McFalls et al 
27 
reported that patients with stable CAD who 
were scheduled for elective vascular operations at 18 Veterans Affairs hospitals were 
randomly assigned to undergo coronary revascularization (CABG or percutaneous 
coronary intervention [PCI]) or medical therapy. After the vascular surgery, there were no 
differences between the 2 groups in the incidence of myocardial infarction or mortality (a 
median follow-up of 2.7 years), and therefore coronary revascularization by either CABG 
or PCI before elective vascular surgery cannot be recommended in patients with stable 
CAD. This randomized study provided evidence that coronary revascularization in 
patients with stable CAD does not provide better protection when compared to current 
medical therapy, which included β-blockers and statins. The study, however, excluded 
patients with symptoms of unstable coronary disease, left main CAD, aortic stenosis, or 
severe left ventricular dysfunction, which are class I indications for CABG based on 
ACC/AHA guidelines for CABG surgery published in 1999.
28 
 
 
In contrast, other studies by Eagle et al,
26 
Landersberg et al,
29 
and Garofalo et al
30 
have 
shown that previous coronary revascularization provides protection against adverse 
cardiac events and mortality after vascular surgery. The causes responsible for the 
difference between the above studies are unclear but probably are due to patient 
populations included in those studies being different. Taken together, for upcoming 
surgery, patients with high-risk CAD (left main or 3-vessel disease, poor left ventricular 
function, and/or diabetes) probably will benefit from coronary revascularization, whereas 
patients with intermediate-risk and stable CAD will be more likely to do better with 
optimal medical therapy.
13,26-30 
 
 
 
CABG versus PCI (angioplasty or stenting) before vascular surgery  
 
In the substudy of the CARP trial, Ward et al 
31 
compared clinical outcomes in patients 
receiving CABG versus PCI as prophylaxis for elective vascular surgery and found that 
compared with patients with PCI (131 patients), patients with CABG (91 patients) had 
fewer myocardial infarctions despite more diseased vessels in the CABG group and 
tended to spend less time in the hospital after the vascular operation. The authors 
concluded that more complete revascularization accounted for the intergroup differences.  
 
 
CABG versus coronary angioplasty before noncardiac surgery  
 
Previous studies have shown that CABG reduces the risk of cardiac complications after 
noncardiac surgery. Whether coronary angioplasty provides equivalent protection is not 
known. In BARI, Hassan et al 
32 
found that rates of myocardial infarction and death after 
noncardiac surgery are similarly low after contemporary bypass surgery or coronary 
angioplasty in patients with multi-vessel CAD in a randomized study.  
 
Coronary stents in surgical patients  
 
Percutaneous transluminal coronary angioplasty (PTCA) was introduced by Gruntzing in 
1977. Sigwart and Puel deployed the first coronary stent in humans in 1986. By 1999, 
stenting or bare metal stents (BMSs) composed 84.2% of all PCIs.33 In 2001, the drug-
eluting stent (DES) was introduced and 2 years later it was approved by the Food and 
Drug Administration in the United States.
34 
At present, most coronary stents have been 
converted to DES in the United States.
34 
PTCA, coronary artery stent, and DES are 3 
landmark developments in interventional cardiology. However, despite the initial 
enthusiasm that resulted in the advent of DES, incomplete endothelialization and stent 
thrombosis continue to plague these devices. Initial studies on animals demonstrated 
complete endothelialization with BMS at 28 days, whereas DES uniformly showed 
incomplete healing at 180 days.
35  
 
 
In 2000, Kaluza et al
36 
first reported on 40 patients treated with BMS who underwent 
noncardiac surgery within 6 weeks of stent implantation. Seven patients had myocardial 
infarction, of which 6 were fatal. Other similar studies have also shown a high incidence 
of cardiovascular complications when noncardiac surgery was performed shortly after 
coronary stenting or PTCA alone.
37,38  
  
The 2007 ACC/AHA for Cardiovascular Angiography and Interventions 
recommendations for the prevention of stent thrombosis after coronary stent implantation 
state that, at a minimum, patients should be treated with clopidogrel 75 mg and aspirin 325 
mg for 1 month after BMS implantation, 3 months after sirolimus DES implantation, 6 
months after paclitaxel DES implantation, and ideally, up to 12 months if they are not at 
high risk for bleeding.
39 
This advisory stresses the importance of 12 months of dual 
antiplatelet therapy after placement of a DES and educating the patient and health care 
providers about hazards of premature discontinuation. It also recommends postponing 
elective surgery for 1 year, and if surgery cannot be deferred, considering the continuation 
of aspirin during the perioperative period in high-risk patients with DES. Nevertheless, in 
a recent prospective observational study from 3 medical institutions, Vicenzi et al 
40 
reported that despite all patients receiving continuous heparin and antiplatelet drugs or 
only shortly discontinued, nearly half of the patients (46 of 103, 44.7%) who received 
coronary artery stents within 1 year had complications after surgery; 4.9% of the patients 
died. All but 2 adverse events (bleeding only) were of a cardiac nature.  
 
 
At present, for the patients with PCI who require surgery, there is still a lack of consensus 
regarding how much time should pass between PCI and noncardiac surgery.
13 
However, 
based on the ACC/ AHA recommendations as above,
39 
elective noncardiac surgery should 
be postponed in patients who recently received coronary stenting for a probable minimum 
of 6 to 8 weeks for BMS and 6 to 12 months for DES. More recently, based on a clinical 
study in 60 patients, Ingraldi et al proposed that although DES is effective in keeping open 
diseased heart arteries, they should not be used for patients who need to have noncardiac 
surgery a short time after an interventional heart procedure; instead, BMS provides a safer 
choice for these patients (abstract at the 2007 Scientific Session of the Society for 
Cardiovascular Angiography and Interventions). 
 
 
Perioperative medical therapy  
 
In recent years, significant progress has been made in medical treatments of 
cardiovascular diseases. Along with the progress, medical interventions with drugs such as 
β-blockers and statins have been shown to reduce the occurrence of perioperative cardiac 
complications, which has brought in the surge of interest on risk modification with 
medical therapies instead of risk stratification with potential coronary revascularization in 
surgical patients.  
 
β-Blocker therapy  
 
The ACC/AHA 2006 Guideline Update on Perioperative β-Blocker Therapy
16 
is a formal 
position statement indicating that performance measures should be limited to class I or 
class III recommendations—those recommendations in which patients should or should 
not have the form of therapy—and that they should not include class IIa or IIb 
recommendations, in which the evidence is less strong and for which opinion dictates the 
class of indications. Class I recommendation includes the following: (1) β-blockers should 
be continued in patients undergoing surgery who are receiving β-blockers to treat angina, 
symptomatic arrhythmias, hypertension, or other ACC/AHA class I guideline indications; 
(2) β-blockers should be given to patients undergoing vascular surgery at high cardiac risk 
owing to the finding of ischemia on preoperative testing. Class III recommendation states 
that β-blockers should not be given to patients undergoing surgery who have absolute 
contra-indications to β-blockade.  
 
 
The best protocol for administration of perioperative β-blockers remains uncertain, 
although previous studies have demonstrated that tight heart rate control by β-blockers 
reduced perioperative myocardial ischemia and improved clinical outcomes.
41,42 
 
 
Statin therapy  
 
Statin therapy is well established for prevention of cardiovascular disease. Statins may 
also reduce postoperative mortality and morbidity via a pleiotropic (non– lipid-lowering) 
effect. Recently, Hindler et al 
43 
conducted a meta-analysis to evaluate the overall effect of 
preoperative statin therapy on postoperative outcomes. They analyzed the data from 12 
retrospective and 3 prospective trials with a total of 223 010 patients and found that 
preoperative statin therapy was associated with 38% and 59% reduction in the risk of 
mortality after cardiac and vascular surgery, respectively. When including noncardiac 
surgery, a 44% reduction in mortality was observed.  
 
 
Nevertheless, so far there is only one RCT on the effect of statin in patients undergoing 
noncardiac surgery carried out in Brazil.
44 
In this study with 50 patients in the treatment 
and 50 in the placebo group, respectively, short-term (45 days) treatment with atorvastatin 
significantly reduced the incidence of major adverse cardiovascular events after vascular 
surgery; that is, only 4 cases in the atorvastatin group had adverse events compared with 
17 cases in the placebo group (8.0% vs 26.0%, P = .031). Despite the very positive 
findings from this study, the trial was small and the treatment effect appears very large 
(69% relative risk reduction), which is inconsistent with the results from other RCTs of 
statins in preventing cardiovascular events.  
α-2-Adrenergic agonist therapy  
 
α-2-Adrenergic agonists, such as clonidine, can be used in those intolerant to β-blocker 
therapy and have been shown to significantly reduce perioperative myocardial ischemia 
and postoperative death.
45 
 
 
Aspirin therapy  
 
Aspirin, as an anti-inflammatory and antiplatelet medicine, has been widely used for long-
term prevention of cardiovascular disease. However, in perioperative medicine, there are 
still no data to support use of aspirin to prevent PMI. Periprocedural withdrawal of aspirin 
may increase cardiovascular complications including ACS, but continuing aspirin 
increases perioperative bleeding by about 1.5 fold.
46 
Preoperative and early postoperative 
aspirin therapy has been reported to improve postoperative outcomes in patients 
undergoing CABG.
47,48 
In patients with vascular surgery, Robless et al
49 
conducted a meta-
analysis of clinical trials of antiplatelet therapy and found that aspirin reduced the 
incidence of myocardial infarction, stroke, and vascular death but the benefit did not reach 
statistical significance. In contrast, in a large, multinational RCT on aspirin therapy as 
prophylaxis for patients undergoing hip fracture surgery, ischemic cardiac events 
(myocardial infarction or death) were found to be higher among patients who received 
aspirin than placebo (hazard ratio 1.33, P = .05).50  
 
 
Despite the progress that has been made, several recent clinical trials (MaVS study,51 
DIPOM trial,
52 
and POBBLE trial 
53) have failed to demonstrate the use of β-blockers in 
the reduction of perioperative cardiac complications, and raised questions: Where did we 
go wrong and shall we reverse the ACC/AHA recommendations on perioperative β-
blockers? 
54 
Further clinical trials (ie, POISE trial,55 and DECEASE-IV study56) are 
ongoing, which may or may not clarify these controversies because the target population, 
the choice of β-blockers, surgical procedures, and other options of the therapy may be 
different. In addition, it should be appreciated that even superbly designed RCTs may be 
inapplicable to large numbers of patients because the patients enrolled may not represent 
the patient population or the patients excluded would normally receive the treatment of 
interest. Nevertheless, those trials will certainly have important implications on whether or 
how to give β blockers to perioperative patients.  
 
 
In the broad field of clinical medicine, previous clinical trials have clearly demonstrated 
that β-blockers provide multiple benefits to patients with CAD and heart failure, such as 
decreasing mortality in patients with acute myocardial infarction, secondary prevention of 
myocardial infarction in post–myocardial infarction patients, significant reduction in 
arrhythmic death or cardiac death in post–myocardial infarction patients, and improving 
survival in patients with heart failure.
57 
In a recent multinational cohort study that included 
44372 patients with ACS in 14 countries, Fox et al 
58 
demonstrated that improvements in 
the management of patients with ACS, including increases in use of β-blockers, are 
accountable for a significant decline in rates of new heart failure and mortality and in rates 
of stroke and myocardial infarction at 6 months. In the field of surgery and 
anesthesiology, Lindenauer et al
59 
conducted a very large retrospective cohort study 
including 663635 patients from 329 hospitals throughout the United States. In this study, 
they found that perioperative administration of β-blockers was associated with a reduced 
risk of death in the hospital among high-risk, but not low-risk, patients undergoing major 
noncardiac surgery, indicating a potential interaction between the effect of β-blockers and 
the extent of CAD risk.  
 
 
Because of the overwhelming number of studies, some with conflicting results, we 
probably should consider the evidence in 2 dimensions, internal validity (RCTs) and 
external validity (retrospective and/or observational studies), and recognize that different 
methods may complement one another. Thus, the intervention adapted ideally should be 
supported by evidence with both high internal and high external validity.  
 
 
In summary, either β-blockers or prophylactic coronary revascularization more likely 
would provide cardiac protection in select patient populations, that is, β-blockers for 
patients with intermediate-risk and stable CAD, and prophylactic coronary 
revascularization for patients with high risk of CAD. On the other hand, statins have 
proven their therapeutic value for a wide range of patients with CAD; up to now, statins 
have also appeared to provide cardiac protection for surgical patients. Nevertheless, given 
that the present RCTs with statins in surgical patients is limited to one small trial in which 
≤100 patients have actually been treated
43,44 
and given that ACC/AHA/National Heart, 
Lung, and Blood Institute clinical advisory on the use and safety of statins has concluded 
that it may be prudent to withhold statins during hospitalization for major surgery because 
of potential side effects such as myopathy,
60 
it is still premature to recommend the routine 
use of statins for all surgical patients with cardiac risk.  
 
 
Years have passed since the cardiac risk index was proposed in 1977; however, the PMI 
conundrum continues. The pathogenetic mechanisms responsible for PMI remain a 
mystery, which hinders us greatly from developing effective clinical strategies to 
prevent/ reduce PMI.  
 
 
We thank Drs. Grunwald and Seltzer for their critical review of the manuscript.  
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